Hope for 'Life', Future for 'Growth' - Lizhu's Recombinant HCG Approved for Marketing
2021 Year 4 Month 15 On the evening of Day, LiZhu Bio-pharmaceutical Co., Ltd. received the "Drug Registration Certificate" issued by the National Medical Products Administration. Recombinant Human Chorionic Gonadotropin for Injection (recombinant HCG ) successfully passed the "Pharmaceutical Administration Law of the People's Republic of China" and relevant regulations, and was issued a drug registration certificate, allowing for production, listing, and sales.
The approval of this product is good news for patients and a positive development for research and innovation in the domestic assisted reproductive technology field.
According to relevant statistics, the incidence of infertility in China has been increasing year by year in recent years. As of 2019, the infertility rate was about 16.40%. With the continuous decline of China's demographic dividend, effective treatment of infertility has become an urgent need of the times. The continuous expansion of market demand and the continuous improvement and maturity of assisted reproductive technologies will lead to a continuous increase in demand for the assisted reproductive technology market.
LiZhu has been a leader in the assisted reproductive technology field for many years. This approved recombinant HCG is the first product of its kind in China and the second in the world, and it is also the first biopharmaceutical product approved by LiZhu Group since the establishment of LiZhu Bio-pharmaceutical Co., Ltd. in 2010. It has broken the long-term technological monopoly of foreign countries, its technological content is at the leading level in the industry, and it has contributed LiZhu's strength to alleviating the current shortage of urinary HCG in China and promoting the national advocacy of independent research and development and innovation.
